Discover
KURA
Kura Oncology, Inc.
10.78
2 x 7.96
2 x 13.74
bid
ask
-
0.19
1.73%
2 @ 04:00 PM
10.89 +0.11 (1.02%)
| Ytd | 3.75% | |
| 1y | 92.50% |
10.70
day range
11.18
5.45
52 week range
12.49
| Open | 10.98 | Prev Close | 10.97 | Low | 10.70 | High | 11.18 | Mkt Cap | 956.99M |
| Vol | 2.06M | Avg Vol | 1.74M | EPS | -3.35 | P/E | N/A | Forward P/E | -3.35 |
| Beta | 0.86 | Short Ratio | 3.22 | Inst. Own | 114.20% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 9.60 | 200-d Avg | 9.46 | 1yr Est | 28.57 |
KURA News
benzinga.com
Citizens Reiterates Market Outperform on Kura Oncology, Maintains $24 Price Target
Citizens analyst Reni J. Benjamin reiterates Kura Oncology (NASDAQ:KURA) with a Market Outperform
benzinga.com
Kura Oncology And Kyowa Kirin Announce Long-Term Results From The Phase 1/2 KOMET-007 Single-Arm Tri
Kura Oncology, Inc. (NASDAQ:KURA) and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin") today
benzinga.com
Kura Oncology Highlights New Clinical And Translational Data Supporting Darlifarnib As Potential Fou
– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response r
benzinga.com
Kura Oncology And Kyowa Kirin Announce Blood Publication Of Phase 1 Ziftomenib Combination Data Show
– 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients